Literature DB >> 11739689

Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice.

Anne C Moore1, Wing-pui Kong, Bimal K Chakrabarti, Gary J Nabel.   

Abstract

The effects of genetic adjuvants on humoral and cell-mediated immunity to two human immunodeficiency virus antigens, Env and Nef, have been examined in mice. Despite similar levels of gene expression and the same gene delivery vector, the immune responses to these two gene products differed following DNA immunization. Intramuscular immunization with a Nef expression vector plasmid generated a humoral response and antigen-specific gamma interferon (IFN-gamma) production but little cytotoxic-T-lymphocyte (CTL) immunity. In contrast, immunization with an Env vector stimulated CTL activity but did not induce a high-titer antibody response. The ability to modify these antigen-specific immune responses was investigated by coinjection of DNA plasmids encoding cytokine and/or hematopoietic growth factors, interleukin-2 (IL-2), IL-12, IL-15, Flt3 ligand (FL), and granulocyte-macrophage colony-stimulating factor (GM-CSF). Coadministration of these genes largely altered the immune responses quantitatively but not qualitatively. IL-12 induced the greatest increase in IFN-gamma and immunoglobulin G responses to Nef, and GM-CSF induced the strongest IFN-gamma and CTL responses to Env. A dual approach of expanding innate immunity by administering the FL gene, together with a cytokine that enhances adaptive immune responses, IL-2, IL-12, or IL-15, generated the most potent immune response at the lowest doses of Nef antigen. These findings suggest that intrinsic properties of the antigen determine the character of immune reactivity for this method of immunization and that specific combination of innate and adaptive immune cytokine genes can increase the magnitude of the response to DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11739689      PMCID: PMC135692          DOI: 10.1128/jvi.76.1.243-250.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

Review 1.  DNA vaccines: immunology, application, and optimization*.

Authors:  S Gurunathan; D M Klinman; R A Seder
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Authors:  S W Barnett; S Lu; I Srivastava; S Cherpelis; A Gettie; J Blanchard; S Wang; I Mboudjeka; L Leung; Y Lian; A Fong; C Buckner; A Ly; S Hilt; J Ulmer; C T Wild; J R Mascola; L Stamatatos
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  HIV-1 DNA vaccines and chemokines.

Authors:  J D Boyer; J Kim; K Ugen; A D Cohen; L Ahn; K Schumann; K Lacy; M L Bagarazzi; A Javadian; R B Ciccarelli; R S Ginsberg; R R MacGregor; D B Weiner
Journal:  Vaccine       Date:  1999-10-01       Impact factor: 3.641

Review 4.  The promise of nucleic acid vaccines.

Authors:  N P Restifo; H Ying; L Hwang; W W Leitner
Journal:  Gene Ther       Date:  2000-01       Impact factor: 5.250

5.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

6.  Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys.

Authors:  D H Barouch; A Craiu; M J Kuroda; J E Schmitz; X X Zheng; S Santra; J D Frost; G R Krivulka; M A Lifton; C L Crabbs; G Heidecker; H C Perry; M E Davies; H Xie; C E Nickerson; T D Steenbeke; C I Lord; D C Montefiori; T B Strom; J W Shiver; M G Lewis; N L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

7.  HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nef p27 and gag p25 proteins.

Authors:  F Michel; A Hoffenbach; P Froussard; P Langlade-Demoyen; M Kaczorek; M P Kieny; F Plata
Journal:  AIDS Res Hum Retroviruses       Date:  1992-04       Impact factor: 2.205

8.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

9.  Tumorigenicity and lysis by natural killers.

Authors:  J L Collins; P Q Patek; M Cohn
Journal:  J Exp Med       Date:  1981-01-01       Impact factor: 14.307

10.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  35 in total

1.  Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity.

Authors:  SangKon Oh; Jay A Berzofsky; Donald S Burke; Thomas A Waldmann; Liyanage P Perera
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

Review 2.  Physical trauma of vaccination acts as a wake-up call to dangers in the skin.

Authors:  Fiona J Culley; Wieslawa Olszewska
Journal:  Immunology       Date:  2003-11       Impact factor: 7.397

Review 3.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

4.  Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.

Authors:  Sima Velashjerdi Farahani; Mohammad Reza Aghasadeghi; Arash Memarnejadian; Sobhan Faezi; Zahra Shahosseini; Mehdi Mahdavi
Journal:  Pathog Glob Health       Date:  2016-04-13       Impact factor: 2.894

5.  Utilizing IL-12, IL-15 and IL-7 as Mucosal Vaccine Adjuvants.

Authors:  Liljana Stevceva; Marcin Moniuszko; Maria Grazia Ferrari
Journal:  Lett Drug Des Discov       Date:  2006       Impact factor: 1.150

Review 6.  Synthetic DNA vaccine strategies against persistent viral infections.

Authors:  Daniel O Villarreal; Kendra T Talbott; Daniel K Choo; Devon J Shedlock; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

7.  An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models.

Authors:  Ciaran D Scallan; Debora W Tingley; Jonathan D Lindbloom; James S Toomey; Sean N Tucker
Journal:  Clin Vaccine Immunol       Date:  2012-11-14

8.  A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates.

Authors:  Dan H Barouch; Zhi-yong Yang; Wing-pui Kong; Birgit Korioth-Schmitz; Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Ayako Miura; John R Mascola; Norman L Letvin; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 9.  Novel vaccine development strategies for inducing mucosal immunity.

Authors:  Yoshiko Fujkuyama; Daisuke Tokuhara; Kosuke Kataoka; Rebekah S Gilbert; Jerry R McGhee; Yoshikazu Yuki; Hiroshi Kiyono; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2012-03       Impact factor: 5.217

10.  CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.

Authors:  Jun Liu; Qigui Yu; Geoffrey W Stone; Feng Yun Yue; Nicholas Ngai; R Brad Jones; Richard S Kornbluth; Mario A Ostrowski
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.